ERBB2 and breast carcinoma: In a phase I/II trial (NCT00841399/NCT00584789) reported by Mittendorf et al. (2014), 195 breast cancer patients (lymph node-positive/negative, HER2/neu by Immunohistochemistry 1–3 +), who have already been treated with standard of care surgery, chemotherapy and radiation and continued to receive prescribed endocrine therapy, were enrolled and 6 withdrew consent.